CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors

Journal of Immunology

Volumn 179, Issue 3, 2007, Pages 1996-2004

  Baatar, Dolgor ^a   Olkhanud, Purevdorj ^a   Newton, Dianne ^b   Sumitomo, Kenya ^a   Biragyn, Arya ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR4; EXOTOXIN; EXOTOXIN 38; HYBRID PROTEIN; NEUROTOXIN; RIBONUCLEASE; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; BETA CHEMOKINE; CC CHEMOKINE RECEPTOR 4; CCL17 PROTEIN, MOUSE; EOSINOPHIL PROTEIN X; IMMUNOTOXIN; MC148 PROTEIN, POXVIRUS MOLLUSCUM CONTAGIOSUM; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; VIRULENCE FACTOR; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RELAPSE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CYTOSOL; DRUG EFFECT; EOSINOPHIL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; PROTEIN BINDING; PSEUDOMONAS; SCID MOUSE; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE; TUMOR CELL; ANIMAL; BIOSYNTHESIS; CELL LINE; CYTOTOXICITY; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PATHOLOGY; TUMOR CELL LINE; TUMOR RECURRENCE;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; CELL DEATH; CELL LINE; CELL LINE, TUMOR; CHEMOKINES, CC; CYTOTOXICITY, IMMUNOLOGIC; EOSINOPHIL-DERIVED NEUROTOXIN; EXOTOXINS; FEMALE; HUMANS; IMMUNOTOXINS; LEUKEMIA, T-CELL, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, CHEMOKINE; VIRAL PROTEINS; VIRULENCE FACTORS;

EID: 34548614008     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.3.1996     Document Type: Article

References (47)

1. Ishida, T., S. Iida, Y. Akatsuka, T. Ishii, M. Miyazaki, H. Komatsu, H. Inagaki, N. Okada, T. Fujita, K. Shitara, et al. 2004. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma. Clin. Cancer Res. 10: 7529-7539.
2. Yoshie, O., R. Fujisawa, T. Nakayama, H. Harasawa, H. Tago, D. Izawa, K. Hieshima, Y. Tatsumi, K. Matsushima, H. Hasegawa, et al. 2002. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 99: 1505-1511.
3. Proudfoot, A. E. 2002. Chemokine receptors: multifaceted therapeutic targets. Nat. Rev. Immunol. 2: 106-115.
4. Sallusto, F., B. Palermo, D. Lenig, M. Miettinen, S. Matikainen, I. Julkunen, R. Forster, R. Burgstahler, M. Lipp, and A. Lanzavecchia. 1999. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur. J. Immunol. 29: 1617-1625.
5. Dieu, M. C., B. Vanbervliet, A. Vicari, J. M. Bridon, E. Oldham, S. Ait-Yahia, F. Briere, A. Zlotnik, S. Lebecque, and C. Caux. 1998. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 188: 373-386.
6. Campbell, M. J., L. Esserman, N. E. Byars, A. C. Allison, and R. Levy. 1990. Idiotype vaccination against murine B cell lymphoma: humoral and cellular requirements for the full expression of antitumor immunity. J. Immunol. 145: 1029-1036.
7. + T lymphocytes with regulatory activity. J. Immunol. 166: 996-1002.
8. + regulatory T cells. J. Exp. Med. 194: 847-853.
9. Stine, J. T., C. Wood, M. Hill, A. Epp, C. J. Raport, V. L. Schweickart, Y. Endo, T. Sasaki, G. Simmons, C. Boshoff, et al. 2000. KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood 95: 1151-1157.
10. Bendall, L. 2005. Chemokines and their receptors in disease. Histol. Histopathol. 20: 907-926.
11. Muller, A., B. Homey, H. Soto, N. Ge, D. Catron, M. E. Buchanan, T. McClanahan, E. Murphy, W. Yuan, S. N. Wagner, et al. 2001. Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56.
12. Longo-Imedio, M. I., N. Longo, I. Trevino, P. Lazaro, and P. Sanchez-Mateos. 2005. Clinical significance of CXCR3 and CXCR4 expression in primary melanoma. Int. J. Cancer 117: 861-865.
13. Walser, T. C., S. Rifat, X. Ma, N. Kundu, C. Ward, O. Goloubeva, M. G. Johnson, J. C. Medina, T. L. Collins, and A. M. Fulton. 2006. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res. 66: 7701-7707.
14. Ishida, T., H. Inagaki, A. Utsunomiya, Y. Takatsuka, H. Komatsu, S. Iida, G. Takeuchi, T. Eimoto, S. Nakamura, and R. Ueda. 2004. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin. Cancer Res. 10: 5494-5500.
15. Jones, D., R. J. Benjamin, A. Shahsafaei, and D. M. Dorfman. 2000. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 95: 627-632.
16. Trentin, L., C. Agostini, M. Facco, F. Piazza, A. Perin, M. Siviero, C. Gurrieri, S. Galvan, F. Adami, R. Zambello, and G. Semenzato. 1999. The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. J. Clin. Invest. 104: 115-121.
17. Cabioglu, N., M. S. Yazici, B. Arun, K. R. Broglio, G. N. Hortobagyi, J. E. Price, and A. Sahin. 2005. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin. Cancer Res. 11: 5686-5693.
18. Gunther, K., J. Leier, G. Henning, A. Dimmler, R. Weissbach, W. Hohenberger, and R. Forster. 2005. Prediction of lymph node metastasis in colorectal carcinoma by expression of chemokine receptor CCR7. Int. J. Cancer 116: 726-733.
19. Ishida, T., A. Utsunomiya, S. Iida, H. Inagaki, Y. Takatsuka, S. Kusumoto, G. Takeuchi, S. Shimizu, M. Ito, H. Komatsu, et al. 2003. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin. Cancer Res. 9: 3625-3634.
20. Louahed, J., S. Struyf, J. B. Demoulin, M. Parmentier, J. Van Snick, J. Van Damme, and J. C. Renauld. 2003. CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/CCL1 and vMIP-I. Eur. J. Immunol. 33: 494-501.
21. Lentzsch, S., M. Gries, M. Janz, R. Bargou, B. Dorken, and M. Y. Mapara. 2003. Macrophage inflammatory protein 1-α (MIP-1α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 101: 3568-3573.
22. Kim, J., H. Takeuchi, S. T. Lam, R. R. Turner, H. J. Wang, C. Kuo, L. Foshag, A. J. Bilchik, and D. S. Hoon. 2005. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J. Clin. Oncol. 23: 2744-2753.
23. Scrivener, S., R. V. Goddard, E. R. Kaminski, and A. G. Prentice. 2003. Abnormal T-cell function in B-cell chronic lymphocytic leukemia. Leuk. Lymphoma 44: 383-389.
24. Niwa, R., E. Shoji-Hosaka, M. Sakurada, T. Shinkawa, K. Uchida, K. Nakamura, K. Matsushima, R. Ueda, N. Hanai, and K. Shitara. 2004. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 64: 2127-2133.
25. + T-cell responses. Blood 107: 4597-4605.
26. Newton, D. L., P. J. Nicholls, S. M. Rybak, and R. J. Youle. 1994. Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophil-derived neurotoxin-anti-transferrin receptor sFv. J. Biol. Chem. 269: 26739-26745.
27. Ruffini, P. A., A. Biragyn, M. Coscia, L. K. Harvey, S. C. Cha, B. Bogen, and L. W. Kwak. 2004. Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. J. Leukocyte Biol. 76: 77-85.
28. Onda, M., Q. C. Wang, H. F. Guo, N. K. Cheung, and I. Pastan. 2004. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res. 64: 1419-1424.
29. Biragyn, A., K. Tani, M. C. Grimm, S. D. Weeks, and L. W. Kwak. 1999. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Biotechnol. 17: 253-258.
30. Biragyn, A., M. Surenhu, D. Yang, P. A. Ruffini, B. A. Haines, E. Klyushnenkova, J. J. Oppenheim, and L. W. Kwak. 2001. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J. Immunol. 167: 6644-6653.
31. Falk, W., R. H. J. Goodwin, and E. J. Leonard. 1980. A 48-well micro chemotaxis assembly for rapid and accurate measurement of leukocyte migration. J. Immunol. Methods 33: 239-247.
32. Yang, D., Q. Chen, S. Stoll, X. Chen, O. M. Howard, and J. J. Oppenheim. 2000. Differential regulation of responsiveness to fMLP and C5a upon dendritic cell maturation: correlation with receptor expression. J. Immunol. 165: 2694-2702.
33. Biragyn, A., P. A. Ruffini, M. Coscia, L. K. Harvey, S. S. Neelapu, S. Baskar, J. M. Wang, and L. W. Kwak. 2004. Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood 104: 1961-1969.
34. Allured, V. S., R. J. Collier, S. F. Carroll, and D. B. McKay. 1986. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc. Natl. Acad. Sci. USA 83: 1320-1324.
35. Li, M., F. Dyda, I. Benhar, I. Pastan, and D. R. Davies. 1995. The crystal structure of Pseudomonas aeruginosa exotoxin domain III with nicotinamide and AMP: conformational differences with the intact exotoxin. Proc. Natl. Acad. Sci. USA 92: 9308-9312.
36. Coscia, M., and A. Biragyn. 2004. Cancer immunotherapy with chemoattractant peptides. Semin. Cancer Biol. 14: 209-218.
37. Godessart, N. 2005. Chemokine receptors: attractive targets for drug discovery. Ann. NY Acad. Sci. 1051: 647-657.
38. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
39. + T cells. J. Exp. Med. 198: 569-580.
40. + regulatory T cells in human ovarian carcinoma. Cancer Res. 65: 5020-5026.
41. Maloney, D. G. 2005. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J. Clin. Oncol. 23: 6421-6428.
42. Boot, J. H., M. E. Geerts, and L. A. Aarden. 1989. Functional polymorphisms of Fc receptors in human monocyte-mediated cytotoxicity towards erythrocytes induced by murine isotype switch variants. J. Immunol. 142: 1217-1223.
43. Kim, D. H., H. D. Jung, J. G. Kim, J. J. Lee, D. H. Yang, Y. H. Park, Y. R. Do, H. J. Shin, M. K. Kim, M. S. Hyun, and S. K. Sohn. 2006. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 108: 2720-2725.
44. Arons, E., L. Sorbara, M. Raffeld, M. Stetler-Stevenson, S. M. Steinberg, D. J. Liewehr, I. Pastan, and R. J. Kreitman. 2005. Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy. Cancer Immunol. Immunother. 55: 1100-1110.
45. Kreitman, R. J., D. R. Squires, M. Stetler-Stevenson, P. Noel, D. J. FitzGerald, W. H. Wilson, and I. Pastan. 2005. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J. Clin. Oncol. 23: 6719-6729.
46. Kreitman, R. J. 2004. Recombinant immunotoxins for the treatment of hematological malignancies. Exp. Opin. Biol. Ther. 4: 1115-1128.
47. + Tregs, regulate effector T cells using FasL. J. Immunol. 178: 4891-4900.